Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    CD44
Show Display Options
Rank Status Study
1 Completed A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
Condition: Neoplasms
Intervention: Drug: RO5429083
2 Completed Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: bivatuzumab mertansine
3 Terminated Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: bivatuzumab mertansine
4 Unknown  Methylation Status of CD44 Promoter Region in Primary Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention:
5 Completed Vascular Access for Hemodialysis and Inflammation
Condition: Vascular Access for Hemodialysis and Inflammation
Intervention:
6 Withdrawn Prognostic Value of Stem Cell Related Markers
Condition: Breast Cancer
Intervention:
7 Terminated Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   CLL;   SLL
Intervention: Drug: A6
8 Unknown  Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Condition: Lung Cancer
Intervention: Procedure: phlebotomy
9 Active, not recruiting
Has Results
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Conditions: Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
10 Completed Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Intervention: Drug: Paclitaxel+Reparixin
11 Completed Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
Conditions: HER2-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Drug: paclitaxel;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Completed GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Conditions: Neoplasms, Oral;   Mouth Neoplasms
Intervention: Drug: GSK1120212
13 Unknown  Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Simvastatin
14 Recruiting 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
Conditions: Lung Carcinoma;   Solitary Pulmonary Nodule;   Cigarette Smoking Behavior
Interventions: Procedure: Computed Tomography;   Radiation: fluorodeoxyglucose F-18;   Radiation: Fluorine F 18 L-glutamate Derivative BAY94-9392;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography;   Procedure: Positron Emission Tomography (PET)
15 Enrolling by invitation Effects of ADSC Therapy in Women With POF
Condition: Premature Ovarian Failure
Intervention: Procedure: Autologous fat grafting
16 Completed Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Neoplasms
Intervention: Drug: bivatuzumab mertansine
17 Not yet recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC).
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
18 Active, not recruiting Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: carboplatin;   Procedure: biopsy
19 Completed Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557
Condition: Asthma
Interventions: Drug: GSK2269557;   Drug: GSK2269557 matching placebo
20 Unknown  Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Biological: monoclonal antibody Ch14.18;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: bone marrow ablation with stem cell support;   Procedure: conventional surgery;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Indicates status has not been verified in more than two years